SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

RYTM

Rhythm Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight • Neutral

The data support setmelanotide's efficacy but are unlikely to materially change near-term revenue. Monitor for regulatory updates in HO label expansion and upcoming quarterly earnings for prescription trends.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$91.31
T+0 close · May 12, 2026 · via day close
Latest settled
+22.77%
T+60 · $112.10
Vs SPY
+18.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $91.31entry
  2. T+1 · 6mo ago +2.64%α +2.06% · $93.72
  3. T+5 · 6mo ago −4.90%α −4.97% · $86.84
  4. T+20 · 5mo ago −6.13%α −4.41% · $85.71
  5. T+60 · 3mo ago +22.77%α +18.38% · $112.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rhythm Pharmaceuticals presented positive clinical data for setmelanotide at ECE 2026, including significant BMI reductions (16.9% at 12 months) and improvements in cardiometabolic risk indices in acquired hypothalamic obesity. The data are encouraging but represent incremental conference presentations rather than a regulatory or financial catalyst.

Key Facts

  • Real-world data showed 16.9% mean BMI reduction at 12 months in acquired HO (n=25, p<0.0001).
  • Phase 3 TRANSCEND post hoc analysis: metabolic syndrome z-score improved -0.9 vs -0.2 placebo (p<0.0001).
  • No new safety signals; adverse events consistent with prior Phase 3 trials.
  • Six posters presented at ECE 2026; none represent regulatory filings or label expansions.

Financial Impact

No financial data provided; impact on revenue is indirect through potential future prescription uptake.

pipelinemarket perception

Risk Factors

  • Clinical data may not translate to broad commercial adoption.
  • Competition from other obesity therapies.
  • Regulatory hurdles for label expansion remain.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292752

Track record

26 reports on RYTM

Performance horizon

9 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  3. Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  4. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  5. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  6. Nov 2, 202613d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
  8. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
  9. Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
  10. Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (11h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026